Calling Interference: Alnylam Stock Offering Garners $150M
By Randy Osborne
Wednesday, January 16, 2013
Riding high after laying to rest its patent skirmish, Alnylam Pharmaceuticals Inc. priced its public offering of 8 million shares without a discount, selling them at Tuesday's closing price of $21.32, for net proceeds of about $151.1 million, or about $173.8 million if the underwriters exercise their full overallotment option of 1.2 million shares.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.